First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Cryoport: the story is balanced — FDA approvals and commercial launches of CAR-T and gene therapies requiring cryogenic logistics (each new therapy…
★ Analysts see FY2026 revenue reaching $194M — +10.3% growth in a single year.
What Moves the Stock
1FDA approvals and commercial launches of CAR-T and gene therapies requiring cryogenic logistics (each new therapy represents potential multi-million dollar annual contract)
2Clinical trial enrollment volumes and Phase 2/3 trial initiations by biopharma clients (leading indicator of future commercial demand)
3Quarterly shipment volumes and average revenue per shipment trends (indicates pricing power and service mix)
4Customer concentration risk and contract renewals with top 10 clients (likely representing 50%+ of revenue)
5Path to profitability metrics including EBITDA margin trajectory and cash burn rate given negative FCF
6Cryogenic shipping solutions and container rentals for cell/gene therapy transport (estimated 50-60% of revenue)
7Logistics services including temperature monitoring, regulatory compliance, and supply chain management (estimated 25-35%)
8Reproductive medicine specimen storage and transport services (estimated 10-15%)
growth - Investors are betting on the structural growth of cell/gene therapy market (estimated 25-30% CAGR through 2030) despite current…
Rising rates create moderate headwinds through two channels: (1) higher cost of capital for unprofitable growth company with negative FCF…
Watch on earnings: FDA calendar for CAR-T and gene therapy BLA approvals (particularly Bluebird Bio, CRISPR Therapeutics, Vertex pipeline assets), Biotech venture capital funding volumes (NVCA quarterly data) as leading indicator of clinical trial activity, Federal funds rate and high-yield credit spreads affecting biotech financing environment.
One Sentence Summary:
Cryoport: the story is balanced — fda approvals and commercial launches of car-t and gene therapies requiring cryogenic logistics (each new therapy represents potential.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.